Eyeing the booming renal therapeutics market, Swiss pharmaceutical giant Novartis AG plans to spend up to $3.5 billion on Chinook Therapeutics. The deal marks the latest in a string of high-profile mergers and acquisition (M&A) deals in the pharma sector over the past roughly half year.
Chinook’s kidney disease specialization in the Novartis M&A equationAt the heart of the deal is Chinook’s specialization in precision medicines for kidney disease.
The rising prevalence of chronic kidney disease, which affects roughly 10% of the global population, according to the National Kidney Foundation, underscores the urgency of addressing renal disorders.
The growing prevalence of diabetes, a core contributor to the rise of renal disorders, has stimulated the market for therapies for chronic kidney disease.
This bar chart shows Novartis acquisitions over the past three years. The transaction amou…